Filing Flows › Evofem Biosciences (EVFM) › Q3 2025
Evofem Biosciences (EVFM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Evofem Biosciences (EVFM) reported revenue of $5.0M for the third quarter 2025 (Q3 2025), +10% from a year earlier and +3% from the quarter before. Operating margin was 19.2%, net loss $1.6M (31.7% of revenue).
Evofem Biosciences, Q3 2025: revenue $5.0M (+10% year over year), operating margin 19.2%, net loss $1.6M, operating cash flow $336K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.0M | +3% | +10% |
| Operating profit | $951K | — | — |
| Net earnings | −$1.6M | — | — |
| Operating cash flow | $336K | — | — |
What changed
Revenue was $5.0M in Q3 2025, up 10% year over year and up 3% from the previous quarter.
Operating profit was $1.0M, a 19.2% margin (up 73.5 points year over year). Total costs fell 42% while revenue rose 10%. The quarter ended with a net loss of $1.6M, narrower than the previous quarter's $1.8M loss. Net interest and other expense of $2.5M was the main reason.
Operating cash flow was $336K. Non-cash charges added back $84K of depreciation and amortization and $23K of share-based compensation. Working capital and other items added $1.8M.
Questions
What was Evofem Biosciences' revenue in the third quarter 2025?
Evofem Biosciences (EVFM) reported revenue of $5.0M for the third quarter 2025 (Q3 2025), +10% from a year earlier and +3% from the quarter before.
Was Evofem Biosciences profitable in the third quarter 2025?
Operating profit was $951K (19.2% of revenue) and net loss $1.6M.
Source: Evofem Biosciences 10-Q on SEC EDGAR.